pantoprazole

Proton pump inhibitors

ATC code: A02BC02 (Pantoprazole)

Mechanism of action

Irreversibly inhibits H+/K+-ATPase (proton pump) in gastric parietal cells. Same mechanism as omeprazole. A distinctive feature of pantoprazole is its weaker CYP2C19 inhibition. This underpinned the 2009 caution about omeprazole–clopidogrel interaction, but the clinical relevance has been refuted by the COGENT RCT (Bhatt DL et al. NEJM 2010) and subsequent studies: no difference in cardiovascular outcomes between DAPT patients on different PPIs. Pantoprazole remains a reasonable choice in clopidogrel-treated patients, but this is no longer a critical advantage.

Indications

Gastroesophageal reflux disease

First line

First-line GERD therapy. PPIs are the most effective agents for acid suppression. Pantoprazole 40 mg once daily 30 minutes before breakfast. Course 4–8 weeks, then attempt dose reduction or on-demand dosing.

NSAID gastropathy prophylaxis

First line

First-line prophylaxis of gastropathy in patients on long-term NSAIDs with risk factors – age over 65, ulcer history, concomitant anticoagulants or corticosteroids. Pantoprazole 20 mg once daily for the duration of NSAID therapy.

Peptic ulcer disease

First line

First-line for peptic ulcer disease. Duodenal ulcer course is 4 weeks, gastric ulcer 8 weeks. In H. pylori eradication, any PPI at double dose twice daily. Pantoprazole is preferred in patients on clopidogrel after coronary stenting.

Practical notes

Timing and administration

Take 30 minutes before the first meal. The proton pump is activated by meal-stimulated signaling, and the drug needs to be circulating at that point. Swallow the tablet whole, do not crush – the enteric coating protects against degradation in gastric acid.

Special situations

In vitro, pantoprazole is a weaker CYP2C19 inhibitor than omeprazole or esomeprazole. This was the historical basis of the 's 2009 caution on the clopidogrel interaction, but the COGENT RCT (Bhatt DL et al. NEJM 2010) and subsequent studies have shown no clinically meaningful difference in cardiovascular outcomes between PPIs in DAPT patients. Current position: PPIs are indicated during dual antiplatelet therapy to reduce GI bleeding; the choice of molecule is not critical. Pantoprazole remains a convenient option in clopidogrel-treated patients, especially when other CYP2C19-sensitive drugs are involved.

Safety

Contraindications

Hypersensitivity to PPIs

Serious adverse effects

Clostridioides difficile-associated diarrhea
Hypomagnesemia with long-term use (over 1 year)
Increased fracture risk with long-term use – hip, wrist, spine
Vitamin B12 deficiency with use over 2 years
Acute interstitial nephritis (rare)

Common adverse effects

Headache
Diarrhea
Nausea
Flatulence
Abdominal pain

PregnancyFDA B

FDA category B. Safety data in pregnancy are limited, but animal studies have shown no teratogenic effect. Used when clearly indicated.

Frequently asked

What is pantoprazole used for?

pantoprazole is evaluated for the following indications with varying evidence strength: NSAID gastropathy prophylaxis (evidence tier A), Gastroesophageal reflux disease (evidence tier A), Peptic ulcer disease (evidence tier A). See the full indication matrix with dosing and citations above on this page.

What are the side effects of pantoprazole?

Common side effects of pantoprazole (≥ 1 in 100): Headache, Diarrhea, Nausea, Flatulence, Abdominal pain. See the Safety section for uncommon and serious reactions.

Is pantoprazole safe during pregnancy?

FDA category B. FDA category B. Safety data in pregnancy are limited, but animal studies have shown no teratogenic effect. Used when clearly indicated.

Who should not take pantoprazole?

pantoprazole is contraindicated in: Hypersensitivity to PPIs. Full list in the Safety section.